

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1498)

TRADING HALT

The board of directors (the “**Board**”) of PuraPharm Corporation Limited (the “**Company**”) hereby announces that, at the request of the Company, trading in the securities of the Company has been halted with effect from 9 a.m. on Thursday, 2 January 2020 pending the release of an announcement pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in relation to a proposed rights issue, which constitutes inside information of the Company.

By order of the Board
Chan Yu Ling, Abraham
Chairman

Hong Kong, 2 January 2020

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie, and Ms. Man Yee Wai, Viola; non-executive director of the Company is Mr. Chow, Stanley; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.